Neauvia Intense Lips 1x1ml

AVAILABLE
Regular price €66.00 EUR
Regular price -11% €74.00 EUR Sale price €66.00 EUR sin IVA

Important Notice

Medical device regulated by the European Medical Device Regulation (MDR), intended exclusively for authorized healthcare professionals. By purchasing, the customer declares to be authorized for their professional activity; false information may entail legal responsibilities.

4,3 / 5

Trusted by doctors and clinics

24 verified reviews on Trustpilot

Read reviews

Neauvia Organic Intense Lips is the reference in the range registered specifically for the lips: 24 mg/ml of hyaluronic acid cross-linked with PEGDE, medium extrusion force and a 27G needle included. The manufacturer defines the injection area as the vermilion and/or the perioral area, which distinguishes it from the rest of the Intense line, aimed at the face.

  • HA 24 mg/ml
  • Cross-linker PEGDE
  • Contents 1 syringe × 1.0 ml
  • Needle 27G included
  • Duration 6 months (mean degradation)
Composition and technology
  • Cross-linked hyaluronic acid: 24 mg/ml.
  • Cross-linker: PEGDE (polyethylene glycol diglycidyl ether).
  • Glycine and L-proline in phosphate buffer solution.
  • No anaesthetic: the formulation does not contain lidocaine; in lip treatment, separate topical or nerve block anaesthesia should be planned.
  • Rheological profile: medium extrusion force, adapted to injection into the labial mucosa and submucosa.

Cross-linking with PEGDE. Neauvia uses polyethylene glycol diglycidyl ether (PEGDE) as its cross-linking agent, instead of the BDDE used by most HA fillers on the market. The manufacturer calls this platform Smart Crosslinking Technology and bases the safety profile of the range on it: no pathological inflammatory reactions detected, no cytotoxic activity, no cross-linker residues after complete degradation of the implant, and reversibility of the filler with hyaluronidase.

Objective reading of the data. PEG is a well-established polymer in pharmaceutical use, and the available publications on the PEG-HA hydrogels from Matex Lab (Zerbinati et al.) describe in vitro biocompatibility and a degree of cross-linking between 2.8 % and 6.2 %. The exact PEGDE concentration is protected by patent and is not published by the manufacturer. To date there is no direct comparative trial of PEGDE versus BDDE with a primary clinical endpoint, so the advantage should be understood as a difference in cross-linking chemistry supported by physicochemical and in vitro data, not as a demonstrated clinical superiority.

Glycine and L-proline. Both proteinogenic amino acids are added to the phosphate buffer solution to adjust the viscoelastic properties of the gel and its swelling resistance, with the aim of controlling the water uptake of the hydrogel in the phase following implantation.

Position within the Neauvia Organic range
ProductHA · cross-linking · extrusion force · plane · area
Hydro Deluxe / Hydro Deluxe Man18 mg/ml · non-cross-linked (linear) + CaHA · low · epidermis and dermis · face and neck
Intense Rheology22 mg/ml · PEG · medium · intradermal and/or subcutaneous · face
Intense Lips24 mg/ml · PEG · medium · vermilion and/or perioral area · lips
Intense Flux26 mg/ml · PEG · medium · intradermal and/or subcutaneous · face
Intense LV26 mg/ml · PEG · medium/high · intradermal and/or subcutaneous · face
Stimulate / Stimulate Man26 mg/ml · PEG + calcium hydroxyapatite · medium/high · subdermis and/or supraperiosteal · face
Intense / Intense Man28 mg/ml · PEG · high · subcutaneous and/or supraperiosteal · face
Intense Rose28 mg/ml · PEG · high · intradermal · labia majora (gynaecological indication)

The entire range shares the same formulation backbone: hyaluronic acid of biotechnological origin cross-linked with PEGDE (polyethylene glycol diglycidyl ether), buffered in phosphate solution and enriched with glycine and L-proline. The difference between references lies in the HA concentration, the resulting rheology and the intended injection plane, not in the cross-linking chemistry. Hydro Deluxe is the only non-cross-linked reference; Stimulate is the only one that incorporates calcium hydroxyapatite in the gel.

Indications and treatment areas

Biodegradable hyaluronic acid hydrogel intended to restore lost volume by injection into the vermilion and/or the perioral area.

  • Volume of the lip body
  • Definition of the vermilion border
  • Perioral area
Technique and treatment protocol
  • Injection area: vermilion and/or perioral area.
  • Needle: 27G, included in the pack.
  • Duration: 6 months mean degradation time according to manufacturer data.
  • Standard linear retrograde threading and submucosal bolus techniques according to the aesthetic objective; prior aspiration in accordance with clinical protocol.
  • Plan for topical anaesthesia or nerve block, since the product does not contain lidocaine.
  • The manufacturer integrates the reference into a specific lip protocol within its combination therapy system.
Technical data
ManufacturerMATEX LAB S.p.A. — via Carlo Urbani 2 ang. via Enrico Fermi, Brindisi (Italy)
Active substanceCross-linked hyaluronic acid 24 mg/ml
Cross-linkerPEGDE (polyethylene glycol)
Other componentsGlycine, L-proline; phosphate buffer solution
AnaestheticNot contained
Presentation1 pre-filled syringe of 1.0 ml
Needle27G included
Extrusion forceMedium
Injection areaVermilion and/or perioral area
Duration6 months mean degradation
ClassificationClass III medical device with CE marking (EU Regulation 2017/745, MDR)
UseQualified healthcare professionals only, trained in hyaluronic acid filler injection techniques
Storage and pack contents

The pack contains: 1 pre-filled syringe of 1.0 ml, 27G needle, package leaflet and traceability labels.

  • Sterile pre-filled syringe, ready for use.
  • Single-use product. Do not reuse or re-sterilise.
  • Store under the conditions indicated on the pack, protected from direct sunlight.
  • Do not use after the expiry date shown on the pack.
  • The traceability labels supplied must be attached to the patient record.
Contraindications and warnings

The manufacturer restricts use to physicians acting in accordance with local legislation and trained in hyaluronic acid filler injection techniques.

Must not be applied in the case of: known hypersensitivity to any of the components of the product; active skin infection, inflammation or lesion in the treatment area; pregnancy and breastfeeding; patients under the age of majority.

Individual assessment: autoimmune disease or immunosuppressive therapy; tendency to hypertrophic or keloid scarring; anticoagulant or antiplatelet therapy; presence of permanent implants in the area.

Do not inject intravascularly. Sterile single-use product: do not reuse or re-sterilise; discard the syringe and the needle after the procedure.

The full contraindications, warnings and possible adverse effects are listed in the package leaflet accompanying the pack and must be consulted before each application.

Medical device intended exclusively for qualified healthcare professionals. Technical information based on the official documentation of MATEX LAB S.p.A. (Neauvia product data sheets and the manufacturer's technical pages) and on peer-reviewed literature on PEG cross-linked hyaluronic acid hydrogels. This data sheet does not replace the instructions for use accompanying the product.